Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1074106.RAYdv5bSe-y_e0GM11f4b-6I-5uNtfoUhiNegybT3YnfM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1074106.RAYdv5bSe-y_e0GM11f4b-6I-5uNtfoUhiNegybT3YnfM130_assertion type Assertion NP1074106.RAYdv5bSe-y_e0GM11f4b-6I-5uNtfoUhiNegybT3YnfM130_head.
- NP1074106.RAYdv5bSe-y_e0GM11f4b-6I-5uNtfoUhiNegybT3YnfM130_assertion description "[These observations provide a strong rationale for the combined use of RSK and PI3K pathway inhibitors to elicit favorable responses in breast cancer patients with activated RSK.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1074106.RAYdv5bSe-y_e0GM11f4b-6I-5uNtfoUhiNegybT3YnfM130_provenance.
- NP1074106.RAYdv5bSe-y_e0GM11f4b-6I-5uNtfoUhiNegybT3YnfM130_assertion evidence source_evidence_literature NP1074106.RAYdv5bSe-y_e0GM11f4b-6I-5uNtfoUhiNegybT3YnfM130_provenance.
- NP1074106.RAYdv5bSe-y_e0GM11f4b-6I-5uNtfoUhiNegybT3YnfM130_assertion SIO_000772 23635776 NP1074106.RAYdv5bSe-y_e0GM11f4b-6I-5uNtfoUhiNegybT3YnfM130_provenance.
- NP1074106.RAYdv5bSe-y_e0GM11f4b-6I-5uNtfoUhiNegybT3YnfM130_assertion wasDerivedFrom befree-2016 NP1074106.RAYdv5bSe-y_e0GM11f4b-6I-5uNtfoUhiNegybT3YnfM130_provenance.
- NP1074106.RAYdv5bSe-y_e0GM11f4b-6I-5uNtfoUhiNegybT3YnfM130_assertion wasGeneratedBy ECO_0000203 NP1074106.RAYdv5bSe-y_e0GM11f4b-6I-5uNtfoUhiNegybT3YnfM130_provenance.